Results of the successful phase 3 TETON-2 study of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented in an oral presentation

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands on September 27 - October 1, 2025.

“On the heels of the remarkable topline results announced earlier this month, we are excited to present additional analyses from the TETON-2 study at ERS this year,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. “Furthermore, we are pleased to present additional interim data from the ADVANCE EXTENSION open-label study evaluating ralinepag for pulmonary arterial hypertension, as well as interim discoveries from the PHINDER study that we believe will improve detection of pulmonary hypertension in patients with interstitial lung disease.”

Posters, mini-symposia, and discussion sessions include:

Oral presentation. Sunday, Sep 28, 11:00 a.m. to 12:15 p.m. CET: Elicium 1/OA1254 – TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis. Presented by Steven D. Nathan, M.D., FCCP, Inova Fairfax Hospital.

Oral presentation. Sunday, Sep 28, 11:00 a.m. to 12:15 p.m. CET: Elicium 1/OA1255 – TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis. Presented by Steven D. Nathan, M.D., FCCP, Inova Fairfax Hospital.

Poster session. Sunday, Sep 28, 12:30 p.m. to 2:00 p.m. CET: PS-36/PA1909 – Interim Results from PHINDER: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection. Presented by Sandeep Sahay, M.D., FCCP, Houston Methodist Hospital.

Poster session. Sunday, Sep 28, 12:30 p.m. to 2:00 p.m. CET: PS-36/PA1913 – High-Resolution Computed Tomography Findings of Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease: Interim Analysis of the PHINDER Study. Presented by David Kiely, M.D., B.Sc. (Hons), FRCP, University of Sheffield.

Poster session. Tuesday, Sep 30, 8:00 a.m. to 9:30 a.m. CET: PS-38/PA5155 – Risk Improvements in Ralinepag Open-Label Extension. Presented by Colin Church, M.D., B.Sc. (Hons), Ph.D., FRCP University of Glasgow.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/pbc.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, anticipated presentations at the upcoming ERS Congress, the potential for the PHINDER study to improve detection of pulmonary hypertension in patients with interstitial lung disease, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 12, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

TYVASO is a trademark of United Therapeutics Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250912614716/en/